Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
130Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.27B | $-245.03M | $-1.41 |
| 2024 | $693.40M | $-705.81M | $-4.60 |
| 2023 | $531.82M | $-214.12M | $-1.73 |
| 2022 | $320.67M | $-289.81M | $-1.97 |
| 2021 | $257.85M | $-259.19M | $-1.75 |
Social Signal Score
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $-0.07 per share
Typical surprise +8.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.04 vs $-0.14beat
- Tue, May 5$-0.13 vs $-0.21beat
- Tue, Feb 24$-0.04 vs $-0.04beat
- Tue, Nov 4$-0.11 vs $-0.17beat
- Fri, Aug 8$-0.22 vs $-0.23beat
- Tue, May 6$-0.24 vs $-0.26beat
Estimates and results for TEM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
TEMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newszacks.com·2d ago·Positive
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.
View source ↗ - Newszacks.com·4d ago·Positive
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.
View source ↗